China Asthma Drug Market Report : Market Research Report

China Asthma Drug Market Report

Published by: Draco Healthcare Consulting LLC

Published: May. 1, 2009 - 103 Pages

Top 20 Pharmaceutical Companies in the Chinese Asthma Drug Hospital Market: Methodology
Chapter I. Clinical Application of Asthma Drugs: Section 1. Definition of Asthma; Section 2. Risk Factors of Asthma; Section 3. Diagnosis and Classification of Asthma; Section 4. Treatment of Asthma; Section 5. Common Asthma Drugs
Chapter II. Analysis of the Chinese Asthma Drug Market: Section 1. Market Size of the Chinese Asthma Drug Hospital Market; Section 2 Market Shares of the Top 20 Asthma Drugs in China (2005-2007); Section 3 Market Shares of Top 20 Pharmaceutical Companies in the China’s Asthma Drug Market (2005-2007); Section 4 Annual Growths of Market Shares of Top 20 Asthma Drugs in China (2005-2007); Section 5 Market Potential of the Top 20 Asthma Drugs
Chapter III. Analysis of Brand Asthma Drugs in China: Section 1: Market Shares of the Top 10 Branded Asthma Drugs in China; Section 2: Major Manufacturers of Asthma Drugs and Their Key Products in China
Chapter IV. R&D of Asthma Drugs.: Section 1. Conventional Medicines; Section 2. Non-conventional Medicines; Section 3. Immunotherapy; Section 4. Gene Therapy; Section 5. Chinese Medicine Treatment; Section 6. Other Therapies
Chapter V. Brand Names, Manufacturers, and Formulas of Asthma Drugs in China: Section 1. Brand Names, Chemical Names, Manufacturers and Formulas of Asthma Drugs in China
Chapter VI. Prices of Asthma Drugs, and Asthma Drugs on the Chinese National Healthcare Insurance List: Section 1: Formulas, Packages, Retail prices, Manufacturers (for Branded Drugs only) of Asthma Drugs in China; Section 2. Asthma Drugs on the Chinese National Healthcare Insurance List
Appendix
Tables: Table 1. Classification of Asthma Prior to Treatme; Table 2. Control Levels of Asthma; Table 3. Market Shares of Top 20 Asthma Drugs in China 2005-2007; Table 4. Annual Sales of Top 20 Asthma Drugs in China 2005-2007; Table 5. Market Shares of the Top 20 Manufacturers of Asthma Drugs 2005-2007; Table 6. Sales of Asthma Drugs from the Top 20 Manufacturers 2005-2007; Table 7. Sales Growth of the Top 20 Asthma Drugs 2006-2007; Table 8. Market Shares of GSK Brand Asthma drugs in the Chinese Hospital Market 2003-2007; Table 9. Sales of GSK Brand Asthma drugs in the Chinese Hospital Market 2003-2007; Table 10. Branded Asthma Drugs by AstraZeneca; Table 11. Market Shares of AstraZeneca Brand Asthma Drugs in the Chinese Hospital Market 2003-2007; Table 12. Sales of AstraZeneca Brand Asthma Drugs in the Chinese Hospital Market 2003-2007; Table 13. Market Shares of Merck Brand Asthma Drugs in the Chinese Hospital Market 2003-2007; Table 14. Sales of Merck Brand Asthma Drugs in the Chinese Hospital Market 2003-2007; Table 15. Market Shares of Boehringer Ingelheim Brand Asthma Drugs in the Chinese Hospital Market 2003-2007; Table 16. Sales of Merck Boehringer Ingelheim Brand Asthma Drugs in the Chinese Hospital Market 2003-2007; Table 17. Market Shares of Sankyo Brand Asthma Drugs in the Chinese Hospital Market 2003-2007; Table 18. Sales of Sankyo Brand Asthma Drugs in the Chinese Hospital Market 2003-2007; Table 19. Market Shares of Fuhe Huaxing Brand Asthma Drugs in the Chinese Hospital Market 2003-2007; Table 20. Sales of Fuhe Huaxing Brand Asthma Drugs in the Chinese Hospital Market 2003-2007; Table 21. Market Shares of Otsuka Brand Asthma Drugs in the Chinese Hospital Market 2003-2007; Table 22. Market Shares of Otsuka Brand Asthma Drugs in the Chinese Hospital Market 2003-2007; Table 23. Brand Names, Chemical Names, Manufacturers and Formulas of Asthma Drugs in China; Table 24. Formulas, Packages, Retail prices, Manufacturers (for Branded Drugs only) of Asthma Drugs in China; Table 25. Chemical Drugs on the Chinese National Healthcare Insurance List; Table 26. Traditional Chinese Medicines (TCMs) on the National Healthcare Insurance
List Figures:: Figure 1. Asthma Management Map; Figure 2. Market Sizes of the Chinese Asthma Drug Market (2003-2007); Figure 3. Market Potentials of the Top Asthma Drugs, China, 2007; Figure 4. Market Shares of the Top 10 Asthma Drugs 2006; Figure 5. Market Shares of the Top 10 Asthma Drugs 2007; Figure 6. Sales of GSK Asthma Drugs 2005, 2006 and 2007; Figure 7. Sales of Branded Asthma Drugs from AstraZeneca 2005, 2006 and 2007
Top 20 Pharmaceutical Companies in the Chinese Asthma Drug Hospital Market (at least > 0.53% of the total Chinese Asthma Drug Hospital Market): Boehringer Ingelheim; Zhejiang Beisheng; AstraZenaca; GSK; Guangdong Huanqiu; Guangzhou Maite-Xinghua; Guilin Nanyao; Hangzhou MSD China; Heilongjiang Fuhe Huaxing; Henan Kaifeng Kangnuo; Hengyang Hengsheng; Jiangsu China Medicine and Technology University; Otsuka Pharmaceutical Co Ltd; Qingzhou Yaowang; Sankyo; Shandong Hualu; Shandong Ruiyang; Shanghai Ethypharm; Sichuan Chengdu Huayu; Zhejiang Changxing

Abstract

According to the 2004 Global Burden of Asthma Report, there were about 300 million asthma patients worldwide. One out of every 250 disease-related deaths was caused by asthma. In China, the incidence rate of asthma patients has continuously increased in the recent years, especially among urban children. The latest survey shows that the incidence rate is 0.7% - 1.5% in adults and 0.11% - 2.03% in children.

Asthma has been known as a costly disease that is difficult to cure. On average asthma treatment will cost a patient over RMB 3000 per year in China. Assuming a national asthma population of 15 - 18 million and a 10% treatment rate, the cost of asthma treatment will be RMB 4.5 - 5.6 billion.

The Chinese asthma drug market reached RMB 1.7 billion in 1999. In 2007, asthma drug sales were RMB 4.855 billion (USD 714 million), an increase of 22.14% from 2006

This report has systemically analyzed the Chinese asthma drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.

Market shares from all major players including multinational and Chinese pharmaceutical companies and their major asthma products are analyzed systemically based on data from significant number of Chinese hospitals. The comprehensive hospital utilization data of major asthma drugs will present you a clear picture of the competition landscape of Chinese asthma drug market and the market potential for your company’s product(s) that already marketed in China or if you are planning to bring your drugs to the China market.

This China Asthma Drug Market Report has been a Must-have reference for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to pharmaceutical companies and interested parties.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

China Asthma Drug Market Report

Table of Contents

Abstract